E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 277, Issue 2 21-2, 1999, Pages

  Hanasato, Norihisa ^a   Oka, Masahiko ^a   Muramatsu, Masashi ^a   Nishino, Mayu ^a   Adachi, Hideyuki ^b   Fukuchi, Yoshinosuke ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b EISAI CO LTD   (Japan)

Author keywords

Adenosine 3',5' cyclic monophosphate; Guanosine 3',5' cyclic monophosphate; Pulmonary arterial remodeling; Right ventricular hypertrophy

Indexed keywords

4 (3 CHLORO 4 METOXYBENZYL)AMINO 1 (4 HYDROXYPIPERIDINO) 6 PHTHALAZINE CARBONITRILE; CYCLIC AMP; CYCLIC GMP; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; HEART OUTPUT; HEART RATE; HEART RIGHT VENTRICLE HYPERTROPHY; HYPOXIA; LUNG; LUNG ARTERY PRESSURE; NONHUMAN; PLASMA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT;

EID: 0032883957     PISSN: 10400605     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajplung.1999.277.2.l225     Document Type: Article

References (36)

1. Ahn, H. S., W. Crim, B. Pitts, and E. J. Sybertz. Calcium-calmodulin-stimulated and cyclic-GMP-specific phosphodiesterases: tissue distribution, drug sensitivity, and regulation of cyclic GMP levels. In: Advances in Second Messenger and Phosphoprotein Research, edited by S. J. Strads and H. Hidaka. New York: Raven, 1992, vol. 25, p. 271-288.
2. Anand-Srivastava, M. B., and G. J. Trachte. Atrial natriuretic factor receptors and signal transduction mechanisms. Pharmacol. Rev. 45: 455-497, 1993.
3. Barst, R. J., L. J. Rubin, W. A. Long, M. D. McGoon, S. Rich, D. B. Badesch, B. M. Groves, V. F. Tapson, R. C. Bourge, B. H. Brundage, S. K. Koerner, D. Langleben, C. A. Keller, S. Murali, B. F. Uretsky, L. M. Clayton, M. M. Jobsis, S. D. Blackburn, Jr., D. Shortino, and J. W. Crow. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N. Engl. J. Med. 334: 296-301, 1996.
4. A-receptor antagonist, attenuates hypoxic pulmonary hypertension in rats. Am. J. Physiol. 266 (Heart Circ. Physiol. 35): H1327-H1331, 1994.
5. Braner, D. A. V., J. R. Fineman, R. Chang, and S. J. Soifer. M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am. J. Physiol. 264 (Heart Circ. Physiol. 33): H252-H258, 1993.
6. Cohen, A. H., K. Hanson, K. Morris, B. Fouty, I. F. McMurtry, W. Clarke, and D. M. Rodman. Inhibition of cyclic 3′-5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J. Clin. Invest. 97: 172-179, 1996.
7. Dinerman, J. L., C. J. Lowenstein, and S. H. Snyder. Molecular mechanisms of nitric oxide regulation. Circ. Res. 73: 217-222, 1993.
8. Dzau, V. J., and G. H. Gibbons. Vascular remodeling: mechanisms and implications. J. Cardiovasc. Pharmacol. 21, Suppl. 1: S1-S5, 1993.
9. Erslev, A. J. Production of erythrocytes. In: Hematology (2nd ed.), edited by W. J. Williams, E. Beutler, A. J. Erslev, and R. W. Rundeles. New York: McGraw-Hill, 1977, p. 203-316.
10. Frostell, C., M. D. Fratacci, J. C. Wain, R. Jones, and M. W. Zapol. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary hypertension. Circulation 83: 2038-2047, 1991.
11. Garg, U. C., and A. Hassid. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Invest. 83: 1774-1777, 1989.
12. Goldberg, M. A., S. P. Dunning, and H. F. Bunn. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 242: 1412-1415, 1988.
13. Grover, R. F. Chronic hypoxic pulmonary hypertension. In: The Pulmonary Circulation: Normal and Abnormal, edited by A. P. Fishman. Philadelphia: University of Pennsylvania Press, 1990, p. 283-299.
14. Hislop, A., and L. Reid. New findings in pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. Br. J. Exp. Pathol. 57: 542-554, 1976.
15. Ichinose, F., C. Adrie, W. E. Hurford, and W. M. Zapol. Prolonged pulmonary vasodilator action of inhaled nitric oxide by zaprinast in awake lambs. J. Appl. Physiol. 78: 1288-1295, 1995.
16. Ishihara, H., H. Adachi, K. Kodama, S. Suzuki, T. Takamura, and H. Tanaka. Pharmacological characterization of a novel, potent, and selective phosphodiesterase inhibitor, E4010 (Abstract). Jpn. J. Pharmacol. 76, Suppl. I: 175P, 1998.
17. Kinsella, J. P., F. Torielli, J. W. Ziegler, D. D. Ivy, and S. H. Abman. Dipyridamole augmentation of response to nitric oxide. Lancet 346: 647-648, 1995.
18. Mason-Garcia, M., and B. S. Beckman. Signal transduction in erythropoiesis. FASEB J. 5: 2958-2964, 1991.
19. McLaughlin, V. V., D. E. Genthner, M. M. Panella, and S. Rich. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N. Engl. J. Med. 338: 273-277, 1998.
20. Morrell, N. W., K. G. Morris, and K. R. Stenmark. Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. Am. J. Physiol. 269 (Heart Circ. Physiol. 38): H1186-H1194, 1995.
21. A inhibitors. Drug News Perspect. 6: 150-156, 1993.
22. Ohnishi, M., M. Oka, M. Muramatsu, K. Sato, S. Kira, and Y. Fukuchi. E4021, a selective phosphodiesterase 5 inhibitor, potentiates the vasodilator effect of inhaled nitric oxide in isolated perfused rat lungs. J. Cardiovasc. Pharmacol. 33: 619-624, 1999.
23. Oka, M., K. G. Morris, and I. F. McMurtry. NIP-121 is more effective than nifedipine in acutely reversing chronic pulmonary hypertension. J. Appl. Physiol. 75: 1075-1080, 1993.
24. Pepke-Zaba, J., T. W. Higgenbottam, A. T. Dinh-Xuan, D. Stone, and J. Wallwork. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet 338: 1173-1174, 1991.
25. Polson, J. B. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu. Rev. Pharmacol. Toxicol. 36: 403-427, 1996.
26. Reily, D. J. Vascular remodeling. In: The Lung, edited by R. G. Crystal and J. B. West. New York: Raven, 1991, p. 1189-1198.
27. Rounds, S., and N. S. Hill. Pulmonary hypertensive diseases. Chest 85: 397-405, 1984.
28. Rubin, L. J. Vasodilator therapy (general aspects). In: The Pulmonary Circulation: Normal and Abnormal, edited by A. P. Fishman. Philadelphia: University of Pennsylvania Press, 1990, p. 479-483.
29. Saeki, T., H. Adachi, Y. Takase, S. Yoshitake, S. Souda, and I. Saito. A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery. J. Pharmacol. Exp. Ther. 272: 825-831, 1995.
30. Sarker, R., D. Gordon, J. C. Stanley, and R. C. Webb. Dual cell cycle-specific mechanisms mediate the antimitogenic effects of nitric oxide in vascular smooth muscle cells. J. Hypertens. 15: 275-283, 1997.
31. Takahashi, T., T. Kanda, M. Inoue, T. Suzuki, I. Kobayashi, K. Kodama, and R. Nagai. A selective type V phosphodiesterase inhibitor, E4021, protects the development of right ventricular overload and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension. Life Sci. 59: PL371-PL377, 1996.
32. Thomas, M. K., S. H. Francis, and J. D. Corbin. Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. J. Biol. Chem. 265: 14964-14970, 1990.
33. Troncy, E., M. Francoeur, and G. Blaise. Inhaled nitric oxide: clinical applications, indications, and toxicology. Can. J. Anaesth. 44: 973-988, 1997.
34. Underwood, D. C., S. Bochnowicz, R. R. Osborn, M. A. Luttmann, and D. W. Hay. Nonpeptide endothelin receptor antagonists. X. Inhibition of endothelin-1-and hypoxia-induced pulmonary pressor responses in the guinea pig by the endothelin receptor antagonist, SB 217242. J. Pharmacol. Exp. Ther. 283: 1130-1137, 1977.
35. Yamaguchi, K., M. Oka, M. Nishino, N. Hanasato, S. Kira, and Y. Fukuchi. E4021, a cGMP phosphodiesterase inhibitor, is a selective pulmonary vasodilator in chronically hypoxic pulmonary hypertensive rats. Nihon Kokyuki Gakkai Zasshi 36: 23-28, 1998.
36. Zapol, W. M., S. Rimar, N. Gillis, M. Marletta, and C. H. Bosken. Nitric oxide and the lung. Am. J. Respir. Crit. Care Med. 149: 1375-1380, 1994.